Abstract
ZBTB34 is a novel zinc finger protein with an unknown function. In this study, the gene expression and survival prognosis of ZBTB34 were analyzed across tumors based on the TCGA datasets. According to the bioinformatics analysis and qPCR results, liver hepatocellular carcinomas exhibit a high level of ZBTB34 expression. Additionally, the experiment supported the bioinformatics analysis findings that ZBTB34 expression was regulated by miR-125b-5p and that ZBTB34 affected ZBTB10, POLR1B, and AUH expression in HepG2 cells. Biological software analysis further revealed that ZBTB34 contains a monopartite nuclear localization signal (NLS). Arginine and lysine inside the putative NLS were substituted using the alanine-scanning mutagenesis method. The findings showed that the ability of ZBTB34 to enter the nucleus was abolished by the alanine substitution of the sequence <sup>320</sup>RGGRARQKRA<sup>329</sup> and the mutation of Lys<sup>327</sup> and Arg<sup>328</sup> residues. ZBTB34 was co-immunoprecipitated with importin α1, importin α3, importin α4, and importin β1, according to the results of the co-immunoprecipitation assay. In conclusion, ZBTB34 is a hepatocellular carcinoma-associated protein with a monopartite NLS. The nuclear import of ZBTB34 is mediated by importin α1, importin α3, importin α4, and importin β1. ZBTB34 performs its biological functions via a putative miR-125b-5p/ZBTB34/(ZBTB10, POLR1B, and AUH) signaling axis in HepG2 cells.
Introduction
Hepatocellular carcinoma (HCC) remains one of the most aggressive and common forms of liver cancer, yet the underlying molecular drivers are still being mapped. Zinc finger proteins (ZFPs) are a massive family of transcription factors that act as "master switches" in the cell, but many, like ZBTB34, have remained "orphans" with unknown functions. To function, these proteins must travel from the cytoplasm into the nucleus. This paper investigates whether ZBTB34 plays a role in cancer progression and, crucially, how it gains entry into the nucleus to exert its influence.
Methods
The authors employed a multi-disciplinary approach combining bioinformatics with molecular biology:
- Bioinformatics: Tools like TIMER2 and GEPIA2 were used to mine TCGA (The Cancer Genome Atlas) and GTEx data, looking for expression patterns and survival correlations across 32 different tumor types.
- Structural Prediction: AlphaFold and NLStradamus identified potential nuclear localization signal (NLS) sequences.
- Experimental Validation: Alanine-scanning mutagenesis and confocal microscopy were used to verify the NLS by tracking GFP-tagged ZBTB34 in HepG2 cells. Co-immunoprecipitation (Co-IP) identified the specific transport proteins (importins) that bind to ZBTB34.
- Clinical Samples: Findings were validated using blood and tissue samples from a cohort of 21 Chinese HCC patients.
Results
Pan-Cancer Expression and Clinical Correlation
Bioinformatics analysis revealed that ZBTB34 is significantly upregulated in several cancers, most notably in liver hepatocellular carcinoma (LIHC). High ZBTB34 expression is a statistically significant predictor of poor overall survival in HCC ($P=0.011$) and correlates with advanced pathological stages.
The Molecular Passport and Transport Machinery
The study pinpointed a 10-amino acid sequence ($^{320}$RGGRARQKRA$^{329}$) as the monopartite NLS. Specifically, Lys327 and Arg328 are critical for nuclear entry; mutating these residues traps the protein in the cytoplasm. ZBTB34 relies on a specific subset of the importin family—importins $\alpha$1, $\alpha$3, $\alpha$4, and $\beta$1—for its transport.
A New Signaling Axis
The paper proposes a regulatory pathway: miR-125b-5p normally regulates ZBTB34. When this balance is disrupted, elevated ZBTB34 levels affect the expression of downstream genes like ZBTB10, POLR1B, and AUH, which are involved in cell growth and telomere maintenance.
Discussion and Future Directions
While this study provides a clear map of ZBTB34's transport and its correlation with liver cancer, some limitations remain. The clinical validation was limited to a relatively small cohort (21 patients), and the exact biochemical mechanism of how ZBTB34 regulates its downstream targets remains to be fully elucidated. Future work should investigate whether blocking the ZBTB34-importin interaction can serve as a viable strategy for future targeted therapies to slow tumor growth in vivo.
Summary updated